Geode Capital Management
LXEO icon

Geode Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

Geode Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.14M Buy
1,747,959
+234,182
+15% +$1.27M ﹤0.01% 2654
2026
Q1 		$8.69M Buy
1,513,777
+67,890
+5% +$481K ﹤0.01% 2459
2025
Q4 		$14.4M Buy
1,445,887
+724,006
+100% +$6.61M ﹤0.01% 2198
2025
Q3 		$4.79M Buy
721,881
+143,800
+25% +$695K ﹤0.01% 2804
2025
Q2 		$2.32M Sell
578,081
-8,435
-1% -$27.7K ﹤0.01% 3091
2025
Q1 		$2.04M Buy
586,516
+19,133
+3% +$84.8K ﹤0.01% 3021
2024
Q4 		$3.73M Buy
567,383
+14,136
+3% +$111K ﹤0.01% 2878
2024
Q3 		$5M Buy
553,247
+256,635
+87% +$3.06M ﹤0.01% 2759
2024
Q2 		$4.76M Buy
296,612
+98,813
+50% +$1.44M ﹤0.01% 2754
2024
Q1 		$3.1M Buy
197,799
+97,378
+97% +$1.52M ﹤0.01% 2934
2023
Q4 		$1.35M Buy
+100,421
New +$1.25M ﹤0.01% 3228

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Geode Capital Management's LXEO Position: Q2 2026 in Review

Geode Capital Management increased its Lexeo Therapeutics (LXEO) stake by 15% in Q2 2026, buying an estimated $1.27M and bringing the position to 1,747,959 shares worth $8.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2654.

Geode Capital Management first reported a position in LXEO in Q4 2023 and has held it in 11 quarters since. The position peaked at $14.4M in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Geode Capital Management held 1,747,959 shares of Lexeo Therapeutics worth $8.14M as of Q2 2026.
  • Geode Capital Management bought 234,182 Lexeo Therapeutics shares in Q2 2026, an estimated $1.27M.
  • Lexeo Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2654 holding.
  • Geode Capital Management first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Geode Capital Management's Lexeo Therapeutics position peaked at $14.4M in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.